Premium
Clinical behavior of borderline ovarian tumors: A study of 150 cases
Author(s) -
Tamakoshi Koji,
Kikkawa Fumitaka,
Nakashima Nobuo,
Tamakoshi Akiko,
Kawai Michiyasu,
Furuhashi Yoshihito,
Hattori SenEi,
Kuzuya Kazuo,
Arii Yoshitaro,
Suganuma Nobuhiko,
Tomoda Yutaka
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199702)64:2<147::aid-jso11>3.0.co;2-3
Subject(s) - medicine , stage (stratigraphy) , serous fluid , ovarian tumor , mucinous tumor , pathological , chemotherapy , ovary , ovarian cancer , gastroenterology , cancer , pancreas , paleontology , biology
Background We evaluated the clinical features, treatment, and survival status of the patients with borderline ovarian tumors. Methods A retrospective review of the charts of 150 patients with borderline ovarian tumor registered at the Tokai Ovarian Tumor Study Group from January 1, 1980, to December 31, 1994, was conducted to obtain clinical and pathological information. Results In stage II and III disease, the numbers of patients with no residual tumor, residual tumor of <2 cm, 2–5 cm, and >5 cm were 9, 10, 3, and 3, respectively. The sizes of residual tumors and corresponding clinical response to chemotherapy were as follows: residual tumor of <2 cm, complete response (CR), 6 patients; no change (NC), 2; progressive disease (PD), 2; tumors 2–5 cm, NC, 1 patient, PD, 2; tumors >5 cm, PD, 3 patients. The survival for patients with residual tumor <2 cm was significantly better than for those with residual tumor from 2–5 cm and of >5 cm ( P < 0.05). The survival for patients with stage II and III serous tumor was significantly longer than that for patients with stage II and III mucinous tumor ( P < 0.05). Conclusion In advanced borderline ovarian tumor, the prognosis of patients with gross residual tumor after initial surgery, and especially with mucinous tumor, was poor. J. Surg. Oncol. 64:147–152. © 1997 Wiley‐Liss, Inc.